Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIC-TAC-SAM: Timing of etoposide initiation in severe sporadic HLH in ICU
2024-511807-41-01Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of etoposide and dexamethasone in haemophagocytic lymphohistiocytosis (HLH) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary composite organ failure progression event. Planned start Feb 2026; status: authorised.
02
Drugs
etoposidedexamethasone
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2024-511807-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511807-41-01.